Drug
Alpha1 Proteinase Inhibitor
Alpha1 Proteinase Inhibitor: highest development phase Post-Market, developed by CSL, Takeda. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- CSL, Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| Alpha1-proteinase inhibitor NCT01651351 | Post-Market | Alpha1-antitrypsin Deficiency |
| Alpha1-proteinase inhibitor NCT00261833 | Post-Market | Alpha1-proteinase Inhibitor Deficiency |
Latest
No recent events.
Follow Alpha1 Proteinase Inhibitor on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.